Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001415889-25-016985
Filing Date
2025-06-12
Accepted
2025-06-12 16:55:30
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 58811
2 JOINT FILING AGREEMENT ex-99-06122025_080633.htm EX-99.1 14203
  Complete submission text file 0001415889-25-016985.txt   74708
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Subject) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92962 | Film No.: 251043649
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304
Business Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

EIN.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G